The U.S. Food and Drug Administration announced another major step in its initiative to streamline the development of biosimilar medicines, which are like “generic” versions of biologic drugs. In new draft guidance issued today, the agency recommended streamlining unnecessary clinical pharmacokinetic (PK) testing when scientifically justified. This change could save...
Understanding the Link Between Inflammation, Cholesterol, and Heart Health This study examined whether inflammation or cholesterol levels are better predictors of heart disease and death in people already taking statins, a common cholesterol-lowering medication. Researchers analyzed data from 31,245 patients across three major...
What the Research Revealed Parkinson’s disease (PD) is a growing neurological disorder with no cure, and current treatments focus on managing symptoms. Some researchers believe that newer glucose-lowering drugs (GLDs) used to treat type 2 diabetes might help reduce the risk of PD because both diseases share similar biological pathways, like insulin...
GLP-1 receptor agonists, medications like semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide, are best known for treating type 2 diabetes and supporting weight loss. But researchers are now exploring something unexpected: could these same drugs also help protect joints in osteoarthritis and strengthen bones in osteoporosis?
A 2025 review in Medicine examined how GLP-1 receptor agonists might affect both conditions. The idea is exciting because osteoarthritis and osteoporosis often occur together in older adults, and currently, no single medication effectively treats both.
GLP-1 receptor agonists are best known as medicines for type 2 diabetes and weight loss. Drugs like semaglutide, liraglutide, and exenatide have become widely used for blood sugar control and obesity. But new research suggests they may also help protect joints and bones. A recent review explores how GLP-1 receptor agonists might reduce inflammation in osteoarthritis...
The U.S. Food and Drug Administration recently announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites. “It’s a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking...